Clinical TrialsSL-325's DR3 receptor blockade is expected to provide more durable protection from inflammation than targeting the TL1A ligand, which could more effectively neutralize the signaling axis in IBD.
Financial PerformanceThe announcement of 1Q25 results showed an EPS of ($0.27), which was better than both the analyst's estimate of ($0.40) and the consensus of ($0.28).
Research And DevelopmentPositive preclinical data for SL-325 was presented at the 20th Congress of ECCO in Inflammatory Bowel Diseases, highlighting its potential as a differentiated approach to current IBD treatments.